Stock comparison
AnaptysBio
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ANAB
AnaptysBio
Market cap
$2.57B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ANAB | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 29F | 77B | LMAT |
| Benjamin Graham | 66D | 89A | LMAT |
| Philip Fisher | 43D | 81C | LMAT |
| Peter Lynch | 77B | 67B | ANAB |
| Joel Greenblatt | 54C | 56D | LMAT |
| Charlie Munger | 35D | 68D | LMAT |
| Terry Smith | 30F | 69D | LMAT |
Side-by-side metrics
| Metric | ANAB | LMAT |
|---|---|---|
| Market cap | $2.57B | $2.23B |
| P/E (TTM) | - | 37.1x |
| EV/EBIT | 55.0x | 36.6x |
| ROIC (TTM) | 14.06% | 9.43% |
| Gross margin | 116.42% | 72.39% |
| Net margin | -11.53% | 24.35% |
| Revenue CAGR 5y | 38.82% | 12.75% |
| EPS CAGR 5y | - | 19.04% |
| Debt / Equity | 21.8x | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ANAB leads on
- P/E (TTM)-vs 37.1x+157%
- Revenue CAGR 5y38.82%vs 12.75%+67%
- Gross margin116.42%vs 72.39%+38%
- ROIC (TTM)14.06%vs 9.43%+33%
LMAT leads on
- Net margin24.35%vs -11.53%+147%
- Dividend yield0.84%vs 0.0%+100%
- Debt / Equity0.5xvs 21.8x+98%
- EV/EBIT36.6xvs 55.0x+33%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.